InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,543.22
(
1.61%
)
US TECH 100
19,021.60
(
2.77%
)
Dow Jones
40,563.06
(
1.39%
)
Brent Oil
80.48
(
1.08%
)
Bitcoin
57,648.80
(
-1.81%
)
Post# of 252897
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120287
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 60504

Thursday, 04/10/2008 12:10:15 AM

Thursday, April 10, 2008 12:10:15 AM

Post# of 252897
MNTA ReadMeFirst

[Updated for presentation of
M118 phase-1 results at ASCPT]


What is MNTA’s business all about?
#msg-26876819 4Q07 CC transcript (2/14/08)
#msg-25513125 Quick primer by ThomasS
#msg-26900396 2008 news flow
#msg-25473104 Capsule explanation of proprietary technology
#msg-19626947 Sugars, peptides and glycoproteins, in that order
#msg-24624700 Apropos to above (2005 PR)
#msg-25803923 Craig Wheeler interview in The Pink Sheet
#msg-25473420 Characterizing a compound by “ruling out” structures
#msg-27114485 US FoB’s are a question of when not if
#msg-27286206 Boston Globe article on MNTA and FoB’s
#msg-26837144 Salient FoB quote from MNTA’s CEO
#msg-26808908 Summary of BioCEO webcast (2/13/08)
#msg-26126852 Summary of Stanford webcast (1/19/08)


Valuation and finances
#msg-26836951 4Q07 financial results
#msg-25373113 Musings on share price (Dew, part 1)
#msg-25609532 Musings on share price (Dew, part 2)
#msg-25373942 Musings on share price (zipjet)
#msg-25377293 Musings on share price (ThomasS, part 1)
#msg-25523826 Musings on share price (ThomasS, part 2)
#msg-25523608 Musings on share price (JR)


Management and BoD
#msg-12824293 Craig Wheeler hired from Chiron
#msg-25779241 Composition of Board of Directors
#msg-25779657 Musings on the BoD (Dew)
#msg-27147833 Insider shareholdings
#msg-27619561 Largest shareholders
#msg-27338039 James Roach appointed CMO
#msg-25377212 Standstill agreement with Novartis


Generic-Lovenox program
#msg-25933221 FDA issues non-approvable letter (Bioworld)
#msg-24636279 Competing Lovenox ANDA’s non-approvable at this time
#msg-27715283 In vitro work probably sufficient for resubmission
#msg-12222305 2006 partnership with Sandoz
#msg-25534402 Economics of the Lovenox partnership
#msg-26740202 Lovenox sells $4B (!) per year
#msg-26739674 Lovenox has 53% of US heparin market by volume
#msg-26882378 Status of SNY’s Lovenox patent
#msg-24627410 Musings on timing of EU submission (Dew)


M118 program
#msg-26897124 “Checklist” rationale for M118 program
#msg-26900300 M118 has blockbuster potential
#msg-27272430 Meeting an unmet need
#msg-26897732 M118 clinical trials
#msg-26809439 Rationale for lead indication in PCI
#msg-28193368 Phase-1 results presented at ASCPT
#msg-25147975 M118 vs oral FXa inhibitors


Generic-Copaxone program
#msg-12222305 Copaxone (M356) is part of 2006 NVS collaboration
#msg-26740147 Copaxone sells more than $1B in US alone
#msg-27177236 Copaxone has 25% worldwide share of MS market
#msg-26893858 Musings on the attractiveness of Copaxone program
#msg-24627410 Speculation on the timeline
#msg-25081126 Musings on switches from interferon (zipjet)


Other programs
#msg-12222305 2006 FoB partnership with Sandoz
#msg-25514154 Speculation on the FoB’s to be developed (ThomasS)
#msg-26260388 Musings on the FoB partnership (Dew)


Competition
#msg-28231619 Existing and future anticoagulants


Feature stories on MNTA and related topics
#msg-27286206 Boston Globe (3/07)
#msg-25160571 WSJ (12/07)
#msg-25933221 Bioworld (11/07)
#msg-23005127 Nature (9/07)
#msg-20308884 Lab Technologist (6/07)
#msg-25803923 The Pink Sheet (3/07)
#msg-13119848 Chemical & Engineering News (9/06)
#msg-25779774 Boston Globe (9/04)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up